Primary Ciliary Dyskinesia (PCD) is a rare genetic disease that results in severe sinus and pulmonary infections and is particularly difficult to treat; however, as George Solomon, MD, explains, researchers have recently made important steps in understanding and treating PCD. He explains the critical link they have established between genotype and phenotype of observed PCD cases, which will lead to genetic-based therapies in the future. Equally important, he says, are the strides made in treating symptoms PCD that can help patients right now: UAB is currently conducting clinical trials exploring treatments that help patients clear mucus from their lungs in order to limit damage throughout the body.